Summary
4.17 0.01(0.24%)06/27/2024
Zentalis Pharmaceuticals LLC (ZNTL)
Zentalis Pharmaceuticals LLC (ZNTL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.24 | -21.77 | -65.01 | -70.59 | -72.99 | -85.08 | 0.00 | -82.11 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.17 | |
| Open | 4.20 | |
| High | 4.25 | |
| Low | 4.01 | |
| Volume | 469,348 | |
| Change | 0.01 | |
| Change % | 0.24 | |
| Avg Volume (20 Days) | 2,942,206 | |
| Volume/Avg Volume (20 Days) Ratio | 0.16 | |
| 52 Week Range | 3.93 - 29.42 | |
| Price vs 52 Week High | -85.83% | |
| Price vs 52 Week Low | 6.11% | |
| Range | -0.95 | |
| Gap Up/Down | -0.62 | |
Fundamentals | ||
| Market Capitalization (Mln) | 295 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 98.22 | |
| Book Value | 8.7050 | |
| Earnings Per Share | -3.5940 | |
| EPS Estimate Current Quarter | -1.2400 | |
| EPS Estimate Next Quarter | -1.3400 | |
| EPS Estimate Current Year | -3.9900 | |
| EPS Estimate Next Year | -6.2800 | |
| Diluted EPS (TTM) | -3.5940 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.3015 | |
| Return on equity (TTM) | -0.4116 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.2048 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 45,305,500 | |
| Shares Float | 31,408,068 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 8.09 | |
| Institutions (%) | 92.46 | |
06/26 14:30 EST - accesswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
06/19 11:25 EST - zacks.com
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
06/18 11:58 EST - globenewswire.com
Investigation Into Zentalis Pharmaceuticals, Inc. (ZNTL) Announced byHolzer & Holzer, LLC
ATLANTA, June 18, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL) complied with federal securities laws. On June 18, 2024, Zentalis announced that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).” Following this news, the price of the Company's stock dropped.
Investigation Into Zentalis Pharmaceuticals, Inc. (ZNTL) Announced byHolzer & Holzer, LLC
ATLANTA, June 18, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL) complied with federal securities laws. On June 18, 2024, Zentalis announced that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).” Following this news, the price of the Company's stock dropped.
06/18 08:44 EST - benzinga.com
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Tuesday, Zentalis Pharmaceuticals Inc ZNTL announced that the FDA has placed a partial clinical hold on the following studies of azenosertib:
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Tuesday, Zentalis Pharmaceuticals Inc ZNTL announced that the FDA has placed a partial clinical hold on the following studies of azenosertib:
06/18 07:57 EST - reuters.com
US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop
Zentalis Pharmaceuticals said on Tuesday the U.S. Food and Drug Administration has placed a partial clinical hold on three studies testing its cancer drug, following the death of two trial participants.
US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop
Zentalis Pharmaceuticals said on Tuesday the U.S. Food and Drug Administration has placed a partial clinical hold on three studies testing its cancer drug, following the death of two trial participants.
06/18 07:00 EST - globenewswire.com
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC). This action follows two recent deaths due to presumed sepsis in the DENALI study.
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC). This action follows two recent deaths due to presumed sepsis in the DENALI study.
06/03 18:00 EST - globenewswire.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on June 3, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 20,000 shares of the Company's common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on June 3, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 20,000 shares of the Company's common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
05/30 07:00 EST - globenewswire.com
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis management is scheduled to participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET.
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis management is scheduled to participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET.
05/29 07:00 EST - globenewswire.com
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three decades of experience as a practicing oncologist and drug developer advancing new cancer therapies.
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three decades of experience as a practicing oncologist and drug developer advancing new cancer therapies.
05/23 17:01 EST - globenewswire.com
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators
05/14 07:00 EST - globenewswire.com
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that members of the management team will participate in a virtual fireside chat during the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO and EHA on May 28, 2024 at 10:30 a.m. ET.
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that members of the management team will participate in a virtual fireside chat during the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO and EHA on May 28, 2024 at 10:30 a.m. ET.
05/07 07:00 EST - globenewswire.com
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025
04/12 14:12 EST - seekingalpha.com
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%. Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024.
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%. Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024.
04/02 16:05 EST - globenewswire.com
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents
02/28 10:56 EST - zacks.com
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.